230 related articles for article (PubMed ID: 15500550)
21. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
22. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma.
Itoh T; Shiro T; Seki T; Nakagawa T; Wakabayashi M; Inoue K; Okamura A
Int J Mol Med; 2000 Aug; 6(2):137-42. PubMed ID: 10891556
[TBL] [Abstract][Full Text] [Related]
23. [Aberrations of tumor suppressor genes in hepatocellular carcinomas].
Fujimoto Y
Hokkaido Igaku Zasshi; 1994 Sep; 69(5):1252-60. PubMed ID: 7868063
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
Tseng PL; Tai MH; Huang CC; Wang CC; Lin JW; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
J Surg Oncol; 2008 Oct; 98(5):349-57. PubMed ID: 18646041
[TBL] [Abstract][Full Text] [Related]
25. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium.
Tsai YY; Cheng YW; Lee H; Tsai FJ; Tseng SH; Chang KC
Mol Vis; 2005 Jan; 11():50-5. PubMed ID: 15682042
[TBL] [Abstract][Full Text] [Related]
26. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma.
Chen TC; Hsieh LL; Kuo TT
J Pathol; 1995 Jul; 176(3):243-7. PubMed ID: 7674087
[TBL] [Abstract][Full Text] [Related]
27. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
29. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
30. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
31. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
32. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
33. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
34. Correlation of mutation and immunohistochemistry of p53 in hepatocellular carcinomas in Korean people.
Lee SN; Park CK; Sung CO; Choi JS; Oh YL; Cho JW; Yoo BC
J Korean Med Sci; 2002 Dec; 17(6):801-5. PubMed ID: 12483005
[TBL] [Abstract][Full Text] [Related]
35. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
36. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation.
Tanaka S; Toh Y; Adachi E; Matsumata T; Mori R; Sugimachi K
Cancer Res; 1993 Jun; 53(12):2884-7. PubMed ID: 8389246
[TBL] [Abstract][Full Text] [Related]
37. Numerical aberrations of chromosome 17 and the p53 locus in small hepatocellular carcinomas.
Yano H; Nanashima A; Hidaka S; Haseba M; Tanaka K; Yamaguchi H; Nakagoe T; Tagawa Y; Nagayasu T
Anticancer Res; 2004; 24(1):111-5. PubMed ID: 15015584
[TBL] [Abstract][Full Text] [Related]
38. Loss of p21 expression is associated with p53 mutations and increased cell proliferation and p27 expression is associated with apoptosis in maxillary sinus squamous cell carcinoma.
Bandoh N; Hayashi T; Takahara M; Kishibe K; Ogino T; Katayama A; Imada M; Nonaka S; Harabuchi Y
Acta Otolaryngol; 2005 Jul; 125(7):779-85. PubMed ID: 16012042
[TBL] [Abstract][Full Text] [Related]
39. Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma.
Hsu HC; Huang AM; Lai PL; Chien WM; Peng SY; Lin SW
Hepatology; 1994 Jan; 19(1):122-8. PubMed ID: 7903951
[TBL] [Abstract][Full Text] [Related]
40. p53 protein expression does not correlate with EBV status in childhood B non-Hodgkin lymphomas.
Klumb CE; Hassan R; Zalcberg IR; Resende LM; Carriço MK; Maia RC
Pediatr Blood Cancer; 2004 Aug; 43(2):115-9. PubMed ID: 15236276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
